BR0208384A - Sìntese enantiosseletiva de compostos intermediários de azetidinona - Google Patents

Sìntese enantiosseletiva de compostos intermediários de azetidinona

Info

Publication number
BR0208384A
BR0208384A BR0208384-1A BR0208384A BR0208384A BR 0208384 A BR0208384 A BR 0208384A BR 0208384 A BR0208384 A BR 0208384A BR 0208384 A BR0208384 A BR 0208384A
Authority
BR
Brazil
Prior art keywords
intermediate compounds
enantioselective synthesis
azetidinone intermediate
compound
formula
Prior art date
Application number
BR0208384-1A
Other languages
English (en)
Other versions
BRPI0208384B1 (pt
Inventor
Xiaoyong Fu
Timothy L Mcallister
T K Thiruvengadam
Chou-Hong Tann
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR0208384A publication Critical patent/BR0208384A/pt
Publication of BRPI0208384B1 publication Critical patent/BRPI0208384B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

"SìNTESE ENANTIOSSELETIVA DE COMPOSTOS INTERMEDIáRIOS DE AZETIDINONA". Este pedido de patente refere-se a um processo para preparar um composto da Fórmula I Fórmula I Este composto é um intermediário usado para produzir compostos que são úteis como agentes hipocolesterolêmicos no tratamento e prevenção de aterosclerose.
BRPI0208384A 2001-03-28 2002-03-25 síntese enantiosseletiva de compostos intermediários de azetidinona BRPI0208384B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27928801P 2001-03-28 2001-03-28
PCT/US2002/009123 WO2002079174A2 (en) 2001-03-28 2002-03-25 Enantioselective synthesis of azetidinone intermediate compounds

Publications (2)

Publication Number Publication Date
BR0208384A true BR0208384A (pt) 2004-06-15
BRPI0208384B1 BRPI0208384B1 (pt) 2016-05-31

Family

ID=23068350

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0208384A BRPI0208384B1 (pt) 2001-03-28 2002-03-25 síntese enantiosseletiva de compostos intermediários de azetidinona

Country Status (29)

Country Link
US (1) US6627757B2 (pt)
EP (1) EP1373230B1 (pt)
JP (1) JP4145663B2 (pt)
KR (1) KR100590342B1 (pt)
CN (1) CN1275949C (pt)
AT (1) ATE305459T1 (pt)
AU (1) AU2002258605B2 (pt)
BG (1) BG66189B1 (pt)
BR (1) BRPI0208384B1 (pt)
CA (1) CA2442219C (pt)
CZ (1) CZ304929B6 (pt)
DE (1) DE60206365T2 (pt)
DK (1) DK1373230T3 (pt)
EA (1) EA006898B1 (pt)
EE (1) EE05453B1 (pt)
ES (1) ES2245733T3 (pt)
HK (1) HK1057546A1 (pt)
HR (1) HRP20030760B1 (pt)
HU (1) HU230229B1 (pt)
IL (2) IL157552A0 (pt)
MX (1) MXPA03008803A (pt)
NZ (1) NZ527852A (pt)
PL (1) PL205952B1 (pt)
RS (1) RS50386B (pt)
SI (1) SI1373230T1 (pt)
SK (1) SK287408B6 (pt)
UA (1) UA75644C2 (pt)
WO (1) WO2002079174A2 (pt)
ZA (1) ZA200306612B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US20040132058A1 (en) 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US7135556B2 (en) 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
MXPA06008124A (es) * 2004-01-16 2007-01-26 Merck & Co Inc Npc1l1 (npc3) y metodos para identificar ligandos del mismo.
EP1807070A1 (en) * 2004-09-29 2007-07-18 Schering Corporation Combinations of substituted azetidinones and cb1 antagonists
NZ555320A (en) 2004-12-03 2010-11-26 Schering Corp Substituted piperazines as CB1 antagonists
US8308559B2 (en) * 2007-05-07 2012-11-13 Jay Chun Paradise box gaming system
TW200726746A (en) * 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
BRPI0611531A2 (pt) * 2005-05-09 2010-09-21 Microbia Inc agentes de acoplamento de benzenofosfonato de organometal e método de geração de ligação carbono-carbono
KR20080017345A (ko) * 2005-05-11 2008-02-26 마이크로비아 인코포레이티드 페놀성 4-비페닐일아제티딘-2-온의 제조방법
CN101222950A (zh) * 2005-05-25 2008-07-16 迈克罗比亚公司 制备4-(联苯基)氮杂环丁-2-酮膦酸的方法
US7635705B2 (en) * 2005-06-20 2009-12-22 Schering Corporation Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
US20070259845A1 (en) * 2005-09-08 2007-11-08 Kansal Vinod K Processes for the preparation of (3R,4S)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe
HU0501164D0 (en) * 2005-12-20 2006-02-28 Richter Gedeon Vegyeszet New industrial process for the production of ezetimibe
JP2009528266A (ja) 2006-01-18 2009-08-06 シェーリング コーポレイション カンナビノイド受容体修飾因子
KR101074968B1 (ko) * 2006-02-16 2011-10-18 고토부키 세이야쿠 가부시키가이샤 광학활성 알코올을 제조하는 방법
US7910698B2 (en) 2006-02-24 2011-03-22 Schering Corporation NPC1L1 orthologues
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
WO2008030382A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
JP2010529148A (ja) * 2007-06-07 2010-08-26 テバ ファーマシューティカル インダストリーズ リミティド エゼチミブ製造のための還元方法
EP2170847A2 (en) * 2007-06-28 2010-04-07 Intervet International BV Substituted piperazines as cb1 antagonists
EP2170846A2 (en) * 2007-06-28 2010-04-07 Intervet International BV Substituted piperazines as cb1 antagonists
WO2009032264A1 (en) * 2007-08-30 2009-03-12 Teva Pharmaceutical Industries Ltd. Processes for preparing intermediates of ezetimibe by microbial reduction
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
SI2329014T1 (sl) 2008-08-29 2015-01-30 Codexis, Inc. Polipeptidi ketoreduktaze za stereoselektivno produkcijo (4s)-3(5s)-5(4-fluorofenil)-5-hidroksipentanoil)-4-fenil-1,3-oksazolidin -2-ona
CA2757722C (en) 2009-04-01 2018-05-22 Matrix Laboratories Ltd. Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
US9102959B2 (en) 2009-08-19 2015-08-11 Codexis, Inc. Ketoreductase polypeptides for the preparation of phenylephrine
EP2566497B1 (en) 2010-05-04 2015-07-29 Codexis, Inc. Biocatalysts for ezetimibe synthesis
WO2012155932A1 (en) 2011-05-17 2012-11-22 Pharmathen S.A. Improved process for the preparation of ezetimibe
CN111518046B (zh) * 2020-06-04 2022-04-15 中山奕安泰医药科技有限公司 依泽替米贝中间体及依泽替米贝的制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2046823A1 (de) 1970-09-23 1972-03-30 Farbwerke Hoechst AG vormals Meister Lucius & Brüning, 6000 Frankfurt Neue Azetidinone-(2) und Verfahren zu deren Herstellung
JPS5628057A (en) 1979-08-13 1981-03-19 Isuzu Motors Ltd Front cab suspension device for tiltable cab
DE3006193C2 (de) 1980-02-19 1984-04-12 Siemens AG, 1000 Berlin und 8000 München Elektrische Anschlußverbindung der Elektroden eines Gasentladungs-Überspannungsableiters
US4680391A (en) 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
JPS61121479A (ja) 1984-11-19 1986-06-09 Mitsubishi Electric Corp 太陽電池素子
JPS61180212A (ja) 1985-02-06 1986-08-12 Asahi Optical Co Ltd 後絞り型写真レンズ
JPS62219681A (ja) 1986-03-20 1987-09-26 Toshiba Corp 光信号処理素子の基準光源
CN87107149A (zh) 1986-10-03 1988-05-18 伊莱利利公司 7-[(间位取代的)苯基甘氨酸]1-碳代-1-去硫头孢菌素
US4803266A (en) 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
EP0333268A1 (en) 1988-03-18 1989-09-20 Merck & Co. Inc. Process for synthesis of a chiral 3-beta hydrogen (3R) 4-aroyloxy azetidinone
IL89835A0 (en) 1988-04-11 1989-12-15 Merck & Co Inc Substituted azetidinones,their preparation and pharmaceutical compositions containing them
US4952689A (en) 1988-10-20 1990-08-28 Taisho Pharmaceutical Co., Ltd. 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation
US4876365A (en) 1988-12-05 1989-10-24 Schering Corporation Intermediate compounds for preparing penems and carbapenems
FR2640621B1 (fr) 1988-12-19 1992-10-30 Centre Nat Rech Scient N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases
US4983597A (en) 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5120729A (en) 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
IL99658A0 (en) 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
JPH04356195A (ja) 1991-05-30 1992-12-09 Kyowa Hakko Kogyo Co Ltd アゼチジノン誘導体の製造法
EP0524595A1 (en) 1991-07-23 1993-01-27 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US5561227A (en) 1991-07-23 1996-10-01 Schering Corporation Process for the stereospecific synthesis of azetidinones
US5688785A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5688787A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
JP2840452B2 (ja) 1993-07-09 1998-12-24 シェリング・コーポレーション アゼチジノンの合成方法
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5631635A (en) * 1995-05-08 1997-05-20 Motorola, Inc. Message/response tracking system and method for a two-way selective call receiving device
US5618707A (en) 1996-01-04 1997-04-08 Schering Corporation Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof
DK0877750T3 (da) 1995-10-31 2002-07-15 Schering Corp Som hypocholesterolemiske midler velegnede, sukkersubstituerede 2-azetidinoner
WO1997016424A1 (en) 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
WO1997021676A1 (en) 1995-12-08 1997-06-19 Smithkline Beecham Plc Azetidinone compounds for the treatment of atherosclerosis
BR9709196A (pt) 1996-04-26 1999-05-25 Smithkline Beecham Plc Derivados de azetidinona para o tratamento de aterosclerose
US5886171A (en) 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
GB9611947D0 (en) 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
AU4326197A (en) 1996-07-09 1998-02-02 Merck & Co., Inc. Pharmaceutical compositions
WO1998005331A2 (en) 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
WO1998014179A1 (en) 1996-10-01 1998-04-09 Cima Labs Inc. Taste-masked microcapsule compositions and methods of manufacture
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
FR2758461A1 (fr) 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
CA2301543C (en) 1997-10-07 2005-05-17 Boehringer Ingelheim (Canada) Ltd. Azetidinone derivatives for the treatment of hcmv infections
US6133001A (en) 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
US6207822B1 (en) * 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
EP1137634B1 (en) 1998-12-07 2005-06-15 Schering Corporation Process for the synthesis of azetidinones
CN1249250C (zh) 1999-04-05 2006-04-05 先灵公司 用于制备1－(4－氟苯基)－3(R)－[3(S)－羟基－3－(4－氟苯基)丙基]－4(S)－(4－羟苯基)－2－β丙内酰胺的立体选择性微生物还原反应
AU4343500A (en) 1999-04-16 2000-11-02 Schering Corporation Use of azetidinone compounds
NZ525722A (en) 2000-12-20 2004-11-26 Schering Corp Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
DK1345895T3 (da) 2000-12-21 2007-05-07 Sanofi Aventis Deutschland Hidtil ukendt diphenylazetidioner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse til behandling af lipidstofskifteforstyrrelser
TWI291957B (en) 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same

Also Published As

Publication number Publication date
DK1373230T3 (da) 2005-11-07
CN1275949C (zh) 2006-09-20
ZA200306612B (en) 2004-10-12
EE05453B1 (et) 2011-08-15
KR100590342B1 (ko) 2006-06-15
EP1373230A2 (en) 2004-01-02
YU74803A (sh) 2006-05-25
AU2002258605B2 (en) 2006-01-12
HRP20030760B1 (en) 2011-07-31
CZ20032610A3 (en) 2004-03-17
EA200300970A1 (ru) 2004-04-29
SK287408B6 (sk) 2010-09-07
CN1500083A (zh) 2004-05-26
EP1373230B1 (en) 2005-09-28
HRP20030760A2 (en) 2004-08-31
ES2245733T3 (es) 2006-01-16
UA75644C2 (en) 2006-05-15
SI1373230T1 (sl) 2005-12-31
JP4145663B2 (ja) 2008-09-03
BG66189B1 (bg) 2011-12-30
WO2002079174A3 (en) 2003-02-27
MXPA03008803A (es) 2004-02-18
BRPI0208384B1 (pt) 2016-05-31
EA006898B1 (ru) 2006-04-28
HUP0303526A3 (en) 2004-11-29
HK1057546A1 (en) 2004-04-08
WO2002079174A2 (en) 2002-10-10
DE60206365T2 (de) 2006-07-06
JP2004532210A (ja) 2004-10-21
RS50386B (sr) 2009-12-31
IL157552A (en) 2009-08-03
NZ527852A (en) 2005-03-24
US6627757B2 (en) 2003-09-30
CA2442219C (en) 2007-09-11
DE60206365D1 (de) 2005-11-03
ATE305459T1 (de) 2005-10-15
KR20030085573A (ko) 2003-11-05
IL157552A0 (en) 2004-03-28
CZ304929B6 (cs) 2015-01-28
HUP0303526A2 (hu) 2004-01-28
CA2442219A1 (en) 2002-10-10
HU230229B1 (hu) 2015-10-28
PL363864A1 (en) 2004-11-29
PL205952B1 (pl) 2010-06-30
SK11862003A3 (sk) 2004-04-06
BG108168A (en) 2004-09-30
EE200300464A (et) 2003-12-15
US20020193607A1 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
BR0208384A (pt) Sìntese enantiosseletiva de compostos intermediários de azetidinona
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
TNSN99006A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MXPA05012268A (es) N-arilsulfonilpiperidinas enlazadas como inhibidores de la gamma-secretasa.
ATE297203T1 (de) Antithrombotische mitteln
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
ATE234282T1 (de) Polymorphe verbindungen
BR0213760A (pt) Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
BR0116212A (pt) 2-azetidinonas açúcar-substituìdas úteis como agentes hipocolesterolêmicos
SE0301368D0 (sv) Chemical compounds
BR0016399A (pt) Processo para produzir compostos de epoxiorganosilìcio
ATE380174T1 (de) Arginin-mimetika als faktor xa-inhibitoren
MXPA04002282A (es) Nuevos compuestos y preparaciones como inhibidores de la catepsina.
HRP20090187T1 (en) Bengamide derivatives and use thereof for the treatment of cancer
BR0009453A (pt) Processo para a preparação de um composto
HUP0000756A2 (hu) Levobupivakain vagy ropivakain alkalmazása migrén kezelésére alkalmas gyógyszerkészítmények előállítására
BR0116721A (pt) Processo para a preparação de (±)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperi dina
BR0007183A (pt) Isonipectoamidas para o tratamento de distúrbios mediados por integrina
BR0113944A (pt) Processo para a produção de compostos quirais
ATE322481T1 (de) Zwischenverbindung zur herstellung von carvedilol
ATE334977T1 (de) Discodermolid-analoga und ihre pharmazeutische verwendung
BR0012493A (pt) Processos para a preparação de um composto, e para manufatura de composto fungicida de benzofenona
BR9914331A (pt) Composto, utilização de composto, e, composição farmacêutica
BR0306625A (pt) acetamidas e benzamidas que são úteis no tratamento de disfunção sexual
WO2005108355A3 (de) Dihydrobenzothiophene

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 263/36, A61P 3/00

Ipc: C07D 263/36 (2011.01)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 31/05/2016, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved